On June 21, 2017, Daniel D. Hoyt informed the Board of
Directors (Board) of Medizone International, Inc. (Company)
that he has decided to retire and will resign from the Board of
Directors and retire from all positions with the Company,
effective immediately. Mr. Hoyt also advised the Board that his
decision is not based on any disagreement with the Company on
any matter relating to the Companys operations, policies or
practices. Mr. Hoyt served as a member of the Audit and
Compensation Committees of the Board. The Board has not
identified a potential replacement for Mr. Hoyt. The members of
the Audit Committee as of the date of this report are Stephen
Meyer, Vincent Caponi, and Dwayne Montgomery, who is the Audit
Chair and the members of the Compensation Committee are Stephen
Meyer, Dwayne Montgomery, and Vincent Caponi who is the
Compensation Chair. The Board has determined that each of these
directors is independent under standards adopted by the Board,
which conform to the standards established by the NASDAQ Stock
Market and applicable regulations of the Securities and
Exchange Commission (Commission). The Board noted that each of
these directors: (1) is not an officer or employee of the
Company, and (2) has no direct or indirect relationship with
the Company that would interfere with the exercise of his
independent judgment in carrying out his responsibilities as a
director. The Board also has determined that each independent
director also qualifies as independent as the term is used in
Item 407 of Regulation S-K and as that term is defined under
NASDAQ Rule 4200(a)(15). In addition, the Board believes that
each member of the Audit Committee is independent as required
under Section 10A(m)(3) of the Securities Exchange Act of 1934,
as amended.

(e) Compensation Agreements

Modification of Stock Options Under the terms of the Medizone
International, Inc. 2014 Equity Incentive Plan (2014 Equity
Incentive Plan), unless otherwise determined by the Board, an
option holder generally may exercise an option granted under
the plan following a separation of the holders service with the
Company only if the exercise occurs within 90 days of the date
of separation from the Company. The Board has determined it
will modify the exercise provisions of stock options granted
previously to Mr. Hoyt under the 2014 Equity Incentive Plan to
permit exercise of such options for a period of up to three
years from the date of Mr. Hoyts resignation (but not beyond
the original expiration date of any such grant). No other terms
or provisions of the option grants will be modified. These
modifications affect two option grants made to Mr. Hoyt. The
first grant was made on April 30, 2014 for the purchase of
250,000 shares of common stock at the exercise price of $0.163
per share. This option will expire on April 30, 2019. The
second grant was made on August 18, 2015 for the purchase of a
total of 1,500,000 shares of common stock at an exercise price
of $0.0877 per share. This option will expire on June 21, 2020,
rather than the original expiration date of August 18, 2020.

Item 7.01 Regulation FD Disclosure.

On June 20, 2017, the Company issued a press release announcing
it had registered to attend the Military Health Systems Vendor
Day on September 27, 2017, at the Defense Medical Logistics
Center on Fort Detrick in Frederick, MD. Vendor Day presents a
unique opportunity to interact directly with a large number of
government agencies and to demonstrate the utility of
AsepticSure.

On June 21, 2017, the Company issued a press release announcing
that the AsepticSure technology had received full electrical
safety approval for all models of AsepticSure. This approval
means that AsepticSure has achieved compliance with applicable
international safety standards. The Company issued a second
press release on June 21, 2017, announcing the retirement of
director Daniel Hoyt from its Board.

Also on June 21, 2017, the Company held an investor webcast to
discuss developments in its commercial strategy. Management has
prepared a slide presentation of materials for the webcast that
will be accessible via the Investor Relations section of the
Companys website:

The press releases from June 20 and June 21, 2017 and the
webcast materials are furnished (not filed) as Exhibit 99.1,
Exhibit 99.2, Exhibit 99.3, and Exhibit 99.4 to this Current
Report on Form 8-K to Regulation FD. The information in this
Item 7.01 shall not be incorporated by reference into any
filing or other document to the Securities Act of 1933, as
amended, except as may be expressly set forth by specific
reference in such filing or document.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits